ADXN Addex Therapeutics Ltd

Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2020 financial results on Thursday March 11, 2021.  Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and the media on Thursday, March 11, 2021 at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST).

Title:                Addex to announce full-year 2020 financial resultsDate:               March 11, 2021Time:               16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST).

Joining the Conference Call:1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.    Dial-In Numbers:

• Switzerland                               +41 44 580 65 22
• UK                                 +44 20 30 09 24 70
• U.S.A                                           +1 87 74 23 08 30
• Other Countries

2: Provide the Operator with the Participation Pin Code: 92320595#       

Link to live event online:1: In the 10 minutes prior to the call start time, sign in online by following this Webex link.2: Password: Welcome

About Addex Therapeutics:Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in Q2 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC who are focused on development for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and the NASDAQ Capital Market and trades under the ticker symbol "ADXN".

Press Contacts:

Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation of clinical trials. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2019, as filed with the SEC on April 27, 2020, the prospectus related to the global offering and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Oct 2024 to Nov 2024

Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Nov 2023 to Nov 2024